Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

This study has been completed.
Jiangsu HengRui Medicine Co., Ltd.
Information provided by (Responsible Party):
Xichun Hu, Fudan University Identifier:
First received: July 10, 2012
Last updated: December 2, 2013
Last verified: August 2013
The hypothesis of this clinical research study is to discover if the study drug apatinib can shrink or slow the growth of pretreated non-triple-negative metastatic breast cancer.

Condition Intervention Phase
Breast Neoplasms
Drug: Apatinib
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-institutional, Open-label, Single Arm Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by Xichun Hu, Fudan University:

Primary Outcome Measures:
  • PFS(Progression free survival) [ Time Frame: 8 Weeks ]

Secondary Outcome Measures:
  • ORR (Objective response rate) [ Time Frame: 8 Weeks ]
  • CBR(Clinical benefit rate) [ Time Frame: 8 Weeks ]
  • OS (Overall survival) [ Time Frame: 8 Weeks ]
  • QoL (Quality of life) [ Time Frame: 8 Weeks ]
  • Toxicity (Number of adverse events) [ Time Frame: 8 Weeks ]

Enrollment: 20
Study Start Date: November 2011
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Apatinib
Apatinib 500mg/d
Drug: Apatinib
The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.

Detailed Description:
Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), and its anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The hypothesis of this clinical research study is to discover if the study drug apatinib can shrink or slow the growth of non-triple-negative breast cancer. The safety of apatinib will also be studied. Patients physical state, symptoms, changes in the size of the tumor, and laboratory findings obtained while on-study will help the research team decide if apatinib is safe and effective in pretreated non-triple-negative metastatic breast cancer patients.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

●≥ 18 and ≤ 70 years of age.

  • ECOG performance status of 0-1.
  • Metastatic breast cancer, confirmed by histological analysis.
  • Have experienced at least 1 and at most 4 regimens, and failed from the last chemotherapy regimen. Pretreated anthracycline, taxanes and capecitabine (any rational reason for no use of capecitabine is acceptable) are mandatory.
  • Women diagnosed with human epidermal growth factor receptor positive (HER2+) should have failed for at least 1 anti-HER2 therapy (any rational reason for no use of anti-HER2 therapy is acceptable). HER2+ is defined as +++ staining on immunohistochemistry or FISH/CISH positive for gene amplification.
  • Women diagnosed with HR+ should have failed for at least 1 hormonal therapy.
  • Have failed for at least one chemotherapy regimen, but at most three regimens(including adjuvant and neo-adjuvant setting).
  • Duration from the last therapy (chemotherapy, radiotherapy, target therapy and operation) is more than 4 weeks (Duration for nitroso or mitomycin is 6 weeks).
  • Have at least one extracranial measurable site of disease according to RECIST 1.0 criteria that has not been previously irradiated.
  • Life expectancy of more than 3 months.
  • Negative serum or urine pregnancy test taken in all women within 7 days before inclusion. Sexually active women of childbearing potential must use a medically acceptable form of contraception from the beginning of the study to 8 weeks after the last dose of the investigated drug.
  • Written informed consent prior to study specific screening procedures.

Exclusion Criteria:

  • Triple-negative breast cancer (ER-, PR- and HER2-. HER2- is defined as 0 or 1+ staining on immunohistochemistry or FISH/CISH negative for gene amplification. )
  • Pregnant or lactating women.
  • Less than 4 weeks from the last clinical trial.
  • Uncontrolled hypertension with mono-drug therapy (>140/90 mm Hg);ischemia of the myocardium (≥ grade 2) or myocardial infarction;arrhythmia(≥ grade 2, QTcF > 470ms for female patients) or New York Heart Association Class III/IV
  • Any factors that influence the usage of oral administration.
  • The cumulative doses of doxorubicin and epirubicin before inclusion have surpassed 300 mg/m2 and 600 mg/m2, respectively.
  • Duration from the last therapy (chemotherapy, radiotherapy, target therapy and operation) is less than 4 weeks (Duration for nitroso or mitomycin is less than 6 weeks).
  • Confirmed brain metastasis.
  • Inadequate hepatic, renal, heart, and hematologic functions (hemoglobin <90g/L, neutrophils < 1.5×10^9/L, platelets < 80×10^9/L , ALT > 2.5 x upper limit of normal (ULN)(5x for liver metastasis), AST > 2.5 x ULN (5x for liver metastasis), serum bilirubin > 1.5 x ULN, serum creatine > 1.0 x ULN, creatinine clearance rate ≤ 50ml/min, LVEF < lower limit of normal (LLN).
  • Abnormal coagulative function, inclined to bleeding or is receiving thrombolytictherapy or anticoagulation.
  • History of arterial/venous embolic events (such as cerebrovascular accident, TIA, deep vein thrombus,and pulmonary embolism)
  • Unhealed wound (> 30 days) or bone fracture.
  • Urine protein ≥++ and confirmed >1.0 g by the 24h quantity.
  • Previous or present history of pulmonary fibrosis,interstitial pneumonia,pneumoconiosis,radiation pneumonitis,drug-related pneumonitis or greatly-impaired pulmonary function.
  • Disability of serious uncontrolled intercurrence infection.
  • Abuse of alcohol or drugs.
  • Have received prior treatment with a VEGFR, PDGFR or s-SRC TKI (Bevacizumab is permitted).
  • Acquired or inherent immunodeficiency; HIV infection; organ transplantation history.
  • The active HBV or HCV infection or HBV DNA ≥10^4/ml.
  • History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.
  • Presence of serious harm to subjects or complication to hinder the completion of the study judged by investigators
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01653561

China, Shanghai
Fudan University Cancer Hospital
Shanghai, Shanghai, China, 200032
Fudan University Cancer Hospital
Shanghai, China, 200032
Sponsors and Collaborators
Fudan University
Jiangsu HengRui Medicine Co., Ltd.
Principal Investigator: Xi-Chun Hu, Doctor Fudan Univeristy Cancer Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Xichun Hu, Deputy director of department of medical oncology, Fudan University Identifier: NCT01653561     History of Changes
Other Study ID Numbers: Fudan BR2012-08
Study First Received: July 10, 2012
Last Updated: December 2, 2013

Keywords provided by Xichun Hu, Fudan University:
Metastatic breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on May 25, 2017